( MENAFN - GlobeNewsWire - Nasdaq) GUILDFORD, United Kingdom, June 10, 2024 (GLOBE NEWSWIRE) -- SiSaf Ltd, a biopharmaceutical company that has developed a range of proprietary Bio-Courier® drug delivery technologies, today announced that a licensee of the ProSilic® variant of its technology has reported positive topline results from a randomised, placebo-controlled, multi-dose Phase II trial evaluating its topical treatment for mild to moderate (patchy) alopecia areata (AA), commonly known as spot baldness. This demonstrates the ability of SiSaf's technology to deliver innovative new formulations that address stability, efficacy and side effect issues. The API in the licensee's drug product is a small molecule with a well-established safety profile in dermatology, which works through modulating the inflammatory response and the proliferation of T-cells by disruption of the signalling pathways.
However, until now the instability of the molecule and its side effects have limited its efficacy and therapeutic application. Formulation with Bio-Courier technology has helped overcome these limitations and has transformed the molecule into a highly effective drug. Dr Suzanne Saffie-Siebert, PhD, founder and Chief Executive Officer of SiSaf said: “We formulated the molecule with ProSilic, one of the variants of our Bio-Courier delivery platform.
This has stabilized the drug and has enabled controlled drug release, which reduces the molecule's oxidative reactivity and boosts its a.